Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Declines By 5.2%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 81,400 shares, a decrease of 5.2% from the August 31st total of 85,900 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Trading Up 9.6 %

Shares of BDRX opened at $0.31 on Wednesday. The company has a 50 day moving average price of $0.52 and a 200-day moving average price of $0.85. Biodexa Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $8.81. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.06.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.